Viatris Seeks To Be Gateway For Mid-Sized Products
Mylan And Pfizer Aiming To Leverage Global Platform
With a global supply chain and commercial platform, the Viatris entity to be formed by the merger of Mylan and Pfizer’s Upjohn unit wants to be the partner of choice for mid-sized products overlooked by companies focused on blockbusters.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.